Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.44 |
| ▸ | TUBB | P07437 | 3/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.44 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8910480 | 0.84 | ACHE (0.52) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL683553 | 0.81 | ACHE (0.54) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL9828544 | 0.81 | ACHE (0.54) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL11124910 | 0.80 | MAPT (0.52) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL27881317 | 0.80 | ACHE (0.48) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL8751285 | 0.77 | ACHE (0.50) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL11951323 | 0.77 | ACHE (0.50) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL11951324 | 0.77 | ACHE (0.50) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL1134650 | 0.77 | ACHE (0.50) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL4304719 | 0.77 | ACHE (0.50) | ACHEMAPTCYP3A4CA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | claimed |
| US-9126987-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-09-08 | — | — | US | disclosed |
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-8420684-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome, Huntington's Disease; hypotensive agents; sleeping/eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 4-Cyclopropylimino-5-(3,4-dihydro-2H-pyran-2-yl)-1-(3-imidazol-1-yl-propyl)-imidazolidin-2-one | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2091948-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2091945-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| EP-2091948-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080214620-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008065141-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008055947-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214620-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | ACHE 4326/4885MAPT 4790/4885CYP3A4 3042/4885 |
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | ACHE 3866/4885MAPT 3228/4885CYP3A4 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.